TELA Bio (TELA) Expected to Announce Quarterly Earnings on Tuesday

TELA Bio (NASDAQ:TELA) is expected to post its Q3 2026 resultson Tuesday, November 10th. Analysts expect TELA Bio to announce earnings of ($0.19) per share and revenue of $20.00 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:30 PM ET.

TELA Bio (NASDAQ:TELA) last issued its earnings results on Monday, August 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.03). TELA Bio had a negative net margin of 51.53% and a negative return on equity of 1,320.81%. The firm had revenue of $19.29 million during the quarter, compared to the consensus estimate of $20.01 million. On average, analysts expect TELA Bio to post ($0.76) EPS for the current fiscal year and ($0.44) EPS for the next fiscal year.

TELA Bio Price Performance

Shares of NASDAQ TELA traded up $0.05 during trading on Tuesday, reaching $0.85. 2,671 shares of the stock traded hands, compared to its average volume of 181,736. TELA Bio has a 52-week low of $0.50 and a 52-week high of $1.50. The company has a 50-day moving average of $1.01 and a 200-day moving average of $0.86. The stock has a market capitalization of $38.33 million, a P/E ratio of -1.10 and a beta of 1.36.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on TELA. Craig Hallum assumed coverage on TELA Bio in a research note on Friday, September 25th. They issued a “buy” rating and a $2.00 price objective on the stock. Wall Street Zen upgraded shares of TELA Bio to a “sell” rating in a research report on Saturday. Weiss Ratings upgraded shares of TELA Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, October 26th. Finally, UBS Group set a $2.00 price target on shares of TELA Bio in a research report on Friday, September 25th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $2.14.

Insider Transactions at TELA Bio

In other news, Director Joseph Capper purchased 25,000 shares of the business’s stock in a transaction on Thursday, September 17th. The stock was purchased at an average cost of $1.22 per share, with a total value of $30,500.00. Following the acquisition, the director directly owned 179,827 shares in the company, valued at approximately $219,388.94. This trade represents a 16.15% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders have purchased 115,000 shares of company stock valued at $119,500. Corporate insiders own 1.10% of the company’s stock.

About TELA Bio

TELA Bio, Inc is a medical technology company that develops and commercializes advanced tissue-reinforcement products for soft-tissue repair and reconstruction. The company’s products are designed to support the repair of damaged or weakened tissue while preserving a more natural tissue response.

TELA Bio’s principal product platform is OviTex Reinforced Tissue Matrix, which combines biologic tissue with polymer reinforcement in a proprietary, textile-like design. OviTex products are used in procedures involving hernia and abdominal wall repair, as well as other soft-tissue reconstruction applications.